Bladder Cancer Clinical Trials

• Diagnosed with intermediate risk non-muscle invasive bladder cancer (IR NMIBC) as defined by American Urological Association (AUA)/Society of Urologic Oncology \[SUO\] Guideline (2020)

• Has undergone adequate transurethral resection of bladder tumor (TURBT; with or without peri-operative chemotherapy) within 60 days prior to randomization:

‣ Recurrence within 1 year, low-grade Ta

⁃ Solitary low-grade Ta \>3 cm

⁃ Low-grade Ta, multifocal

⁃ Solitary high-grade Ta, ≤3 cm

⁃ Low-grade T1

• Patients with T1 disease should undergo resection at the base of the lesion and biopsies should contain muscle fibres.

∙ Restage TURBT may be done at the discretion of the investigator